In patients with lung metastasis and a MAPK pathway mutation plus a high CD133 expression, both OS and PFS were significantly shorter than in patients with either MAP kinase wild-type tumours and/or low CD133 expression (OS: 48.1 vs. 67.4 months, HR 2.37 [95% CI: 1.20–4.67], p = 0.01); PFS: 19.0 vs. 28.5 months, HR 1.86 [95% CI: 1.01–3.43], p = 0.04) (Online Resource 6). Here, PROM1 is linked to neoplasm.